An 8-week randomised, double-blind, parallel, multiple dose trial comparing NNC0123-0000-0338 in a tablet formulation and insulin glargine in subjects with type 2 diabetes currently treated with oral antidiabetic therapy

Trial Profile

An 8-week randomised, double-blind, parallel, multiple dose trial comparing NNC0123-0000-0338 in a tablet formulation and insulin glargine in subjects with type 2 diabetes currently treated with oral antidiabetic therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Insulin 338 (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Primary endpoint has not been met. (Fasting plasma glucose), as per an American Diabetes Association Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top